83 related articles for article (PubMed ID: 19000056)
21. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
22. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
[TBL] [Abstract][Full Text] [Related]
23. Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC).
Holm NT; Abreo F; Johnson LW; Li BD; Chu QD
Breast Cancer Res Treat; 2009 Jan; 113(2):293-9. PubMed ID: 18270814
[TBL] [Abstract][Full Text] [Related]
24. Clinical implication of p53 overexpression in breast cancer patients younger than 50 years with a triple-negative subtype who undergo a modified radical mastectomy.
Lee DS; Kim SH; Suh YJ; Kim S; Kim HK; Shim BY
Jpn J Clin Oncol; 2011 Jul; 41(7):854-66. PubMed ID: 21719749
[TBL] [Abstract][Full Text] [Related]
25. Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors.
Hanrahan EO; Broglio KR; Buzdar AU; Theriault RL; Valero V; Cristofanilli M; Yin G; Kau SW; Hortobagyi GN; Rivera E
Cancer; 2005 Sep; 104(6):1158-71. PubMed ID: 16047352
[TBL] [Abstract][Full Text] [Related]
26. Clinical features and survival analysis of T1mic, a, bN0M0 breast cancer.
Li J; Liu X; Tong Z
Jpn J Clin Oncol; 2012 Jun; 42(6):471-6. PubMed ID: 22493058
[TBL] [Abstract][Full Text] [Related]
27. Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer.
Span PN; Tjan-Heijnen VC; Manders P; Beex LV; Sweep CG
Oncogene; 2003 Jul; 22(31):4898-904. PubMed ID: 12894232
[TBL] [Abstract][Full Text] [Related]
28. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.
Colleoni M; Viale G; Zahrieh D; Pruneri G; Gentilini O; Veronesi P; Gelber RD; Curigliano G; Torrisi R; Luini A; Intra M; Galimberti V; Renne G; Nolè F; Peruzzotti G; Goldhirsch A
Clin Cancer Res; 2004 Oct; 10(19):6622-8. PubMed ID: 15475452
[TBL] [Abstract][Full Text] [Related]
30. Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin-docetaxel neoadjuvant chemotherapy: a cohort study.
Kai K; Arima N; Miyayama H; Yamamoto Y; Iwase H; Nishimura R
Breast Cancer; 2009; 16(1):42-8. PubMed ID: 18504642
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
32. [Breast-conservation treatment for early invasive breast cancer: prognostic factors for survival after salvage treatment of local recurrence].
Fodor J
Magy Onkol; 2007; 51(2):127-31. PubMed ID: 17660868
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer.
Lee J; Im YH; Lee SH; Cho EY; Choi YL; Ko YH; Kim JH; Nam SJ; Kim HJ; Ahn JS; Park YS; Lim HY; Han BK; Yang JH
Cancer Chemother Pharmacol; 2008 Apr; 61(4):569-77. PubMed ID: 17508214
[TBL] [Abstract][Full Text] [Related]
34. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP.
Schneider J; Lucas R; Sánchez J; Ruibal A; Tejerina A; Martín M
Anticancer Res; 2000; 20(6B):4373-7. PubMed ID: 11205274
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
Guarneri V; Broglio K; Kau SW; Cristofanilli M; Buzdar AU; Valero V; Buchholz T; Meric F; Middleton L; Hortobagyi GN; Gonzalez-Angulo AM
J Clin Oncol; 2006 Mar; 24(7):1037-44. PubMed ID: 16505422
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
[TBL] [Abstract][Full Text] [Related]
38. Molecular predictive factors for local recurrence and distant metastasis of breast cancer after lumpectomy with postoperative radiation therapy.
Amornmarn R; Bui MM; Prempree TB; Masood S
Ann Clin Lab Sci; 2000 Jan; 30(1):33-40. PubMed ID: 10678581
[TBL] [Abstract][Full Text] [Related]
39. Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer.
Gordon NH; Silverman P; Lasheen W; Meinert J; Siminoff LA
Breast Cancer Res Treat; 2007 May; 102(3):301-12. PubMed ID: 17033926
[TBL] [Abstract][Full Text] [Related]
40. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
